CardioGenesis Corporation to Report 2006 Fourth Quarter and Year-End Results on March 27th

IRVINE, Calif., March 20 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation , announced that the company will release results for its fourth quarter and full year ended December 31, 2006 prior to market open on Tuesday, March 27, 2007. The company also said that President Richard P. Lanigan and Senior Vice President and Chief Financial Officer William R. Abbott will host an investor conference call that day at 12:00 p.m. Eastern time (9:00 a.m. Pacific time) to review the company's financial results and business outlook.

The call is open to all interested investors through a live audio web broadcast via the Internet at www.cardiogenesis.com. The call will be archived on the company's web site and will be available for playback for seven days beginning shortly after the live webcast.

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The Company's market leading Holmium: YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease. Surgical products and accessories for the Company's minimally invasive Percutaneous Myocardial Channeling (PMC) procedure are currently being marketed in Europe and other international markets.

For more information on the Company and its products, please visit the Cardiogenesis company website at http://www.cardiogenesis.com or the direct to patient website at http://www.heartofnewlife.com.

CONTACT: William R. Abbott, Senior Vice President and Chief FinancialOfficer of Cardiogenesis Corporation, +1-949-420-1800

Web site: http://www.cardiogenesis.com/